lobbying_activities: 1266176

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1266176	79271210-134a-4b94-aac8-083981f42251	Q2	CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.	8511	ONYX PHARMACEUTICALS	2012	second_quarter	MED	Innovation in biotechnology; patient access to treatments; FDA accelerated approval process; orphan drugs for rare diseases, health disparities, drug shortages. HR 4132 Faster Access to Specialized Treatments (FAST) Act; S.2113 Transforming the Regulatory Environment to Accellerate Access to Treatments (TREAT) Act; HR 2245/S.296: Preserving Access to Lifesaving Medications Act; S.3187, Food and Drug Administration Safety and Innovation Act	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE	30000		0	0	2012-07-17T13:09:54.003000-04:00